Dr. Sonpavde discusses key data presented during the 2021 Genitourinary Cancers Symposium in urothelial carcinoma and anticipated research directions with immunotherapy, chemotherapy, and antibody-drug conjugates.
Welcome to OncLive On AirTM! I’m your host today, Jessica Hergert.
OncLive On AirTM is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, we had the pleasure of speaking with Guru P. Sonpavde, MD, director of Bladder Cancer and a physician at Dana-Farber Cancer Institute, to discuss some of the main highlights from the 2021 Genitourinary Cancers Symposium in urothelial carcinoma, including key findings from the phase 3 CheckMate 274 trial, the EV-201 and EV-301 trials, and the RETAIN BLADDER trial, among others.
According to Sonpavde, the CheckMate 274 trial captured significant attention during the 2021 Genitourinary Cancers Symposium. However, he explained that immunotherapy is not the only promising approach under study in urothelial carcinoma, citing an abundance of research regarding antibody-drug conjugates (ADCs) and novel agents as reason for excitement.
In our exclusive interview, Sonpavde discussed promising research in urothelial carcinoma and anticipated research directions with immunotherapy, chemotherapy, and ADCs.